Non-MAPK13 off-target messenger RNAs

Non-MAPK13 off-target mRNAs refer to the set of messenger RNA transcripts that are inadvertently affected by therapeutic interventions intended to target Mitogen-Activated Protein Kinase 13 (MAPK13), also known as p38 delta (UniProt: P53778). This phenomenon is a significant concern in the development of oligonucleotide-based therapies, such as siRNAs or antisense oligonucleotides (ASOs), where off-target effects occur due to partial sequence complementarity with unintended transcripts (Jackson et al., Nature Biotechnology, 2003). While MAPK13 is a validated target for treating airway hyper-responsiveness and mucus overproduction in chronic obstructive pulmonary disease (COPD) (Woodruff et al., Journal of Clinical Investigation, 2012), the modulation of non-target mRNAs can lead to cellular toxicity or the disruption of essential physiological pathways. In drug discovery, these off-targets are identified through high-throughput transcriptomic profiling (RNA-seq) to ensure the safety and specificity of the lead candidate. Therefore, this entry does not represent a single therapeutic target but rather a safety parameter used to evaluate the precision of MAPK13-directed agents. Minimizing these interactions is crucial for reducing the risk of adverse drug reactions in clinical settings. The identification of these transcripts helps researchers refine chemical modifications or sequence designs to improve the therapeutic index of the drug.

Other names

Off-target transcriptsNon-specific mRNA targetsUnintended gene targetsMAPK13 off-targets

Unintended sequence-specific or non-specific interaction leading to the degradation, sequestration, or translational inhibition of messenger RNA molecules other than the primary target, MAPK13.